Natera Inc
Change company Symbol lookup
Select an option...
NTRA Natera Inc
VIVC Vivic Corp
LAD Lithia Motors Inc
SBUX Starbucks Corp
HYLN Hyliion Holdings Corp
NIO NIO Inc
F Ford Motor Co
GM General Motors Co
PG Procter & Gamble Co
GE General Electric Co
Go

Health Care : Biotechnology | Mid Cap Blend
Company profile

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).

Closing Price
$67.26
Day's Change
-1.07 (-1.57%)
Bid
--
Ask
--
B/A Size
--
Day's High
69.97
Day's Low
65.61
Volume
(Heavy Day)
Volume:
502,695

10-day average volume:
386,047
502,695

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, October 30, 2020
International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal Diagnosis (ISPD) position statement recommending the use of cfDNA screening in twin pregnancies. The...(PR Newswire)

October 29, 2020
Natera Announces Third Quarter 2020 Earnings Conference Call

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020, after the market close on November 5, 2020. Natera will host a conference...(PR Newswire)

NIPT for Average Risk Now Covered for 139 Million Commercial Lives

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that a major health plan has extended coverage for non-invasive prenatal testing (NIPT) to all singleton pregnancies,1 representing 17 million...(PR Newswire)

October 21, 2020
Natera to Present New Data at ASN Kidney Week 2020 Showing Clinical Differentiation of the Prospera(TM) Test

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data at the 2020 American Society of Nephrology (ASN) Kidney Week virtual meeting taking place October 22-25, 2020. The...(PR Newswire)

October 08, 2020
Natera's Panorama(R) NIPT Receives Average Risk Coverage for an Additional 24 Million Lives

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Centene, a major healthcare insurance company, has extended coverage of the Panorama non-invasive prenatal test (NIPT) to all pregnant women...(PR Newswire)

October 05, 2020
Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness Challenge

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has teamed up with the George Lopez Foundation to create the #GLFTrickShot Challenge, a social media fundraising campaign for kidney patients in need that...(PR Newswire)

Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reports that the U.S. District Court of Delaware has rejected all of ArcherDX's challenges in Natera's ongoing patent infringement action. (PR Newswire)

October 02, 2020
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera(TM)

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE(R)), a CDK4/6...(PR Newswire)

September 24, 2020
Medicare Issues Draft Local Coverage Determination for Signatera(TM) in Immunotherapy Response Monitoring

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has issued a draft local coverage determination (LCD) to provide expanded coverage for circulating...(PR Newswire)

September 14, 2020
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, announced an expansive program to improve care for organ transplant patients with a history of cancer, using the Signatera(TM) test for molecular residual disease (MRD)...(PR Newswire)

September 11, 2020
Natera's Signatera(TM) MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California, has finalized a final local coverage article (LCA) to provide...(PR Newswire)

Natera Announces Pricing of Follow-On Offering

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public of $60.00 per share. Closing of the offering is...(PR Newswire)

September 10, 2020
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept. 14, 2020...(PR Newswire)

September 09, 2020
Natera Launches Proposed Follow-On Offering

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day...(PR Newswire)

September 03, 2020
Natera Receives Final Medicare Coverage for its Signatera(TM) MRD Test in Stage II-III Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has finalized a local coverage determination (LCD) to provide Medicare benefits for serial use of...(PR Newswire)

September 02, 2020
SMART Study Data for Aneuploidy and 22q Unblinded

Natera, Inc. (NASDAQ: NTRA), a pioneer and leader in cell-free DNA testing, today announced the unblinding of the SMART clinical trial data, and the validation of an artificial intelligence-based (AI) platform as part of its Panorama non-invasive...(PR Newswire)

September 01, 2020
Study Shows Clinical Utility of the Prospera(TM) Test in Nephrology Practice

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a prospective, randomized controlled trial showing clinical utility of the Prospera test. The study concluded that practicing...(PR Newswire)

August 27, 2020
Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative agreement with Mass General Cancer Center (MGCC) of Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase...(PR Newswire)

August 18, 2020
Joint Guideline from ACOG and SMFM Supports use of Non-Invasive Prenatal Testing (NIPT) for all Pregnant Women

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive prenatal testing, announced a joint guideline released yesterday by the American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM), regarding the use of...(PR Newswire)

August 07, 2020
Natera Files Additional Suit Against ArcherDX

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed suit yesterday against ArcherDX, Inc. for infringement of Natera's U.S. Patent No. 10,731,220 (the "'220 Patent"). The complaint was filed in the U.S. District...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.